Literature DB >> 33942238

miR-21 Exerts Anti-proliferative and Pro-apoptotic Effects in LPS-induced WI-38 Cells via Directly Targeting TIMP3.

Jin-Xiu Li1,2, You Li3, Tian Xia4,5, Feng-Yan Rong6,7.   

Abstract

Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease, which was caused by a complex interplay of inflammatory responses and chronic damage. miR-21 is increased in patients with IPF, but its function in the embryonic lung-derived diploid fibroblasts cells subjected to LPS is elusive. miRNA expression profile was obtained from GEO database and target genes of miRNAs were forecasted by TargetScan. To mimic the LPS-induced injury, different concentrations of LPS were applied to treat WI-38 cells. Functional in vitro experiments were conducted to examine the role of miR-21 and TIMP3. Luciferase report assay was performed to verify the relationship between miR-21 and TIMP3. qRT-PCR, western blotting, and ELISA were conducted to detect the levels of the related miRNAs, proteins, and inflammatory factors. miR-21 presented higher levels in interstitial pneumonia patients and LPS-induced WI-38 cells. Overexpression of miR-21 was negatively correlated with the proliferative capability of LPS-treated WI-38 cells. miR-21 directly targets TIMP3. TIMP3 restored the suppressive impact of miR-21 mimic on the proliferation, while TIMP3 alleviated the promoting impact of miR-21 mimic on the apoptosis of WI-38 cells treated by LPS. miR-21 inhibited Bcl-2 but increased Bax, cleaved caspase-3, and cleaved caspase-9. Besides, miR-21 elevated the levels of IL-6 and IL-β but reduced the IL-10, which were weakened by TIMP3. Totally, miR-21 aggravated the LPS-induced lung injury and modulated inflammatory responses by targeting TIMP3.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Apoptosis; Apoptosis-associated protein; Idiopathic pulmonary fibrosis; Inflammatory factors; Proliferation; TIMP3; miR-21

Mesh:

Substances:

Year:  2021        PMID: 33942238     DOI: 10.1007/s12013-021-00987-w

Source DB:  PubMed          Journal:  Cell Biochem Biophys        ISSN: 1085-9195            Impact factor:   2.194


  41 in total

Review 1.  Pathogenesis of idiopathic pulmonary fibrosis.

Authors:  Paul J Wolters; Harold R Collard; Kirk D Jones
Journal:  Annu Rev Pathol       Date:  2013-09-13       Impact factor: 23.472

2.  Identification of serum microRNA-21 as a biomarker for early detection and prognosis in human epithelial ovarian cancer.

Authors:  Yun-Zhao Xu; Qing-Hua Xi; Wen-Liang Ge; Xiao-Qian Zhang
Journal:  Asian Pac J Cancer Prev       Date:  2013

3.  EMPIRE Registry, Czech Part: Impact of demographics, pulmonary function and HRCT on survival and clinical course in idiopathic pulmonary fibrosis.

Authors:  Martina Doubková; Jan Švancara; Michal Svoboda; Martina Šterclová; Vladimír Bartoš; Martina Plačková; Ladislav Lacina; Monika Žurková; Ilona Binková; Radka Bittenglová; Vladimíra Lošťáková; Zdeněk Merta; Lenka Šišková; Richard Tyl; Pavlína Lisá; Hana Šuldová; František Petřík; Jana Pšikalová; Vladimír Řihák; Tomáš Snížek; Pavel Reiterer; Jiří Homolka; Pavlína Musilová; Jaroslav Lněnička; Peter Palúch; Roman Hrdina; Renata Králová; Hana Hortvíková; Jana Strenková; Martina Vašáková
Journal:  Clin Respir J       Date:  2017-09-26       Impact factor: 2.570

4.  A Biogenesis Step Upstream of Microprocessor Controls miR-17∼92 Expression.

Authors:  Peng Du; Longfei Wang; Piotr Sliz; Richard I Gregory
Journal:  Cell       Date:  2015-08-06       Impact factor: 41.582

5.  A methodology for the combined in situ analyses of the precursor and mature forms of microRNAs and correlation with their putative targets.

Authors:  Gerard J Nuovo; Terry S Elton; Patrick Nana-Sinkam; Stefano Volinia; Carlo M Croce; Thomas D Schmittgen
Journal:  Nat Protoc       Date:  2009-01-08       Impact factor: 13.491

6.  Micro RNAs: the future of idiopathic pulmonary fibrosis therapy.

Authors:  Tara Vinyette Saco; Prasanna Tamarapu Parthasarathy; Young Cho; Richard Lockey; Narasaiah Kolliputi
Journal:  Cell Biochem Biophys       Date:  2015-01       Impact factor: 2.194

7.  The European IPF registry (eurIPFreg): baseline characteristics and survival of patients with idiopathic pulmonary fibrosis.

Authors:  Andreas Guenther; Ekaterina Krauss; Silke Tello; Jasmin Wagner; Bettina Paul; Stefan Kuhn; Olga Maurer; Sabine Heinemann; Ulrich Costabel; María Asunción Nieto Barbero; Veronika Müller; Philippe Bonniaud; Carlo Vancheri; Athol Wells; Martina Vasakova; Alberto Pesci; Matteo Sofia; Walter Klepetko; Werner Seeger; Fotios Drakopanagiotakis; Bruno Crestani
Journal:  Respir Res       Date:  2018-07-28

8.  Clinical profile of unclassifiable interstitial lung disease: Comparison with chronic fibrosing idiopathic interstitial pneumonias.

Authors:  Daniel Traila; Cristian Oancea; Emanuela Tudorache; Ovidiu Fira Mladinescu; Bogdan Timar; Voicu Tudorache
Journal:  J Int Med Res       Date:  2017-07-31       Impact factor: 1.671

Review 9.  Clinical course and management of idiopathic pulmonary fibrosis.

Authors:  Caitlin Quinn; Amy Wisse; Stephenie T Manns
Journal:  Multidiscip Respir Med       Date:  2019-12-02

10.  Longitudinal clinical outcomes in a real-world population of patients with idiopathic pulmonary fibrosis: the PROOF registry.

Authors:  Wim A Wuyts; Caroline Dahlqvist; Hans Slabbynck; Marc Schlesser; Natacha Gusbin; Christophe Compere; Sofie Maddens; Yuan-Chi Lee; Klaus-Uwe Kirchgaessler; Karen Bartley; Benjamin Bondue
Journal:  Respir Res       Date:  2019-10-24
View more
  1 in total

1.  Ssc-MiR-21-5p and Ssc-MiR-615 Regulates the Proliferation and Apoptosis of Leydig Cells by Targeting SOX5.

Authors:  Qi Tang; Yanghai Zhang; Linxiu Yue; Hongying Ren; Chuanying Pan
Journal:  Cells       Date:  2022-07-21       Impact factor: 7.666

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.